- Date 16 May 2018
- Documents : 4
- Economic analysis
- History
Listen
ZYTIGA (abiraterone acetate), androgen synthesis inhibitor
Reason for request
High clinical benefit for newly diagnosed high-risk hormone-sensitive metastatic prostate cancer and moderate clinical added value compared to androgen deprivation alone.
-
ZYTIGA has been granted a marketing authorisation, in combination with prednisone or prednisolone, for the treatment of newly diagnosed high-risk hormone-sensitive metastatic prostate cancer, for adults, in combination with androgen deprivation therapy (ADT).
-
A phase III study has demonstrated the superiority of the ZYTIGA + ADT + prednisone or prednisolone combination compared to ADT alone, in terms of overall survival. Exploratory analyses suggest a gain in quality of life compared to ADT alone.
-
It is not possible to determine its role compared to the docetaxel + ADT combination, due to the methodological limitations of the sole indirect comparison meta-analysis available.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| moderate |
la Commission considère que ZYTIGA en association à la suppression androgénique (ADT) apporte une ASMR modérée (ASMR III) par rapport à l’ADT seul, chez les patients atteints de cancer de la prostate métastatique hormono-sensible à haut risque nouvellement diagnostiqué, en association avec la prednisone ou la prednisolone. |
-
